Clinical Trials Logo

Gastrointestinal Dysmotility clinical trials

View clinical trials related to Gastrointestinal Dysmotility.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04880538 Completed - Clinical trials for Gastrointestinal Dysmotility

Enteric Neural Precursor Cells (ENPC) in the Human Gut

Start date: April 26, 2021
Phase:
Study type: Observational

The study aim is to acquire human tissues to (a) understand the structure and organization of the human Enteric Nervous System; (b) perform a molecular transcriptomic profile of individual cells residing in the human gut; (c) study the turnover rates of individual cell types by Fluorescence-activated cell sorting-aided C14 dating of cells; and finally (d) culture the human gut-derived cells characterize the human adult enteric neural stem cell and study its potential for Neuro-glial differentiation. This study will advance our knowledge of the the cellular and molecular correlates of changes in the Enteric Nervous System that are associated with disorders of motility.

NCT ID: NCT01296620 Completed - Clinical trials for Gastrointestinal Dysmotility

Ulimorelin Study of Efficacy and Safety (ULISES 008)

Start date: February 2011
Phase: Phase 3
Study type: Interventional

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection

NCT ID: NCT01285570 Completed - Clinical trials for Gastrointestinal Dysmotility

Ulimorelin Study of Efficacy and Safety (ULISES 007)

ULISES
Start date: January 2011
Phase: Phase 3
Study type: Interventional

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.

NCT ID: NCT01280344 Completed - Clinical trials for Gastrointestinal Dysmotility

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

Start date: April 2011
Phase: Phase 2
Study type: Interventional

Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.